4,430 Shares in Express Scripts Holding Co (ESRX) Acquired by MANA Advisors LLC
MANA Advisors LLC bought a new position in shares of Express Scripts Holding Co (NASDAQ:ESRX) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 4,430 shares of the company’s stock, valued at approximately $306,000.
Other hedge funds have also bought and sold shares of the company. SeaCrest Wealth Management LLC bought a new stake in shares of Express Scripts in the fourth quarter valued at about $105,000. Wealthcare Advisory Partners LLC lifted its holdings in shares of Express Scripts by 364.7% in the first quarter. Wealthcare Advisory Partners LLC now owns 1,529 shares of the company’s stock valued at $106,000 after purchasing an additional 1,200 shares in the last quarter. Aevitas Wealth Management Inc. bought a new stake in shares of Express Scripts in the fourth quarter valued at about $128,000. Financial Gravity Companies Inc. bought a new stake in shares of Express Scripts in the fourth quarter valued at about $142,000. Finally, Archford Capital Strategies LLC bought a new stake in shares of Express Scripts in the first quarter valued at about $157,000. Hedge funds and other institutional investors own 85.70% of the company’s stock.
ESRX has been the topic of a number of research reports. Zacks Investment Research lowered Express Scripts from a “buy” rating to a “hold” rating in a report on Friday, March 2nd. Jefferies Financial Group set a $91.00 price target on Express Scripts and gave the company a “buy” rating in a report on Wednesday, February 28th. BidaskClub upgraded Express Scripts from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. Bank of America began coverage on Express Scripts in a report on Tuesday, February 27th. They issued an “underperform” rating and a $77.00 price target on the stock. Finally, Raymond James upgraded Express Scripts from an “underperform” rating to a “market perform” rating in a report on Thursday, March 8th. Four research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have assigned a buy rating to the stock. Express Scripts presently has a consensus rating of “Hold” and an average price target of $82.46.
Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings results on Wednesday, May 2nd. The company reported $1.77 earnings per share for the quarter, topping analysts’ consensus estimates of $1.76 by $0.01. The firm had revenue of $24.77 billion for the quarter, compared to the consensus estimate of $24.80 billion. Express Scripts had a return on equity of 25.41% and a net margin of 4.59%. The business’s revenue was up .5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.33 earnings per share. equities research analysts predict that Express Scripts Holding Co will post 9.07 EPS for the current year.
In other Express Scripts news, insider Christine Houston sold 19,889 shares of the business’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $76.69, for a total transaction of $1,525,287.41. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.79% of the stock is owned by insiders.
Express Scripts Company Profile
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.